[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,496
  • Shares Outstanding, K 12,383
  • Annual Sales, $ 290 K
  • Annual Income, $ -12,600 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 1.51
  • Price/Sales 33.12
  • Price/Cash Flow N/A
  • Price/Book 0.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.54
  • Most Recent Earnings $-0.22 on 05/13/26
  • Next Earnings Date 08/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 3
  • High Estimate $-0.21
  • Low Estimate $-0.24
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) +56.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6500 +5.55%
on 06/12/26
0.9886 -30.60%
on 05/15/26
-0.2139 (-23.77%)
since 05/12/26
3-Month
0.6000 +14.35%
on 03/30/26
1.1200 -38.74%
on 04/17/26
-0.0789 (-10.31%)
since 03/12/26
52-Week
0.5480 +25.20%
on 01/29/26
2.2200 -69.09%
on 07/23/25
-1.2339 (-64.27%)
since 06/12/25

Most Recent Stories

More News
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohorts...

APRE : 0.6861 (-10.31%)
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051 Two partial responses observed with continued encouraging tolerability in the ongoing...

APRE : 0.6861 (-10.31%)
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech

Analysts have initiated bullish coverage of Aprea Therapeutics with price targets up to 6x current levels, citing the superior safety profile and $700M peak sales potential of its WEE1 inhibitor program...

AZN : 178.75 (-1.94%)
ZNTL : 3.75 (+6.53%)
ACRV : 1.4800 (+2.78%)
SDGR : 14.45 (-1.03%)
APRE : 0.6861 (-10.31%)
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery...

APRE : 0.6861 (-10.31%)
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051

Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer

AZN : 178.75 (-1.94%)
ZNTL : 3.75 (+6.53%)
MRK : 119.05 (-1.42%)
APRE : 0.6861 (-10.31%)
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery...

APRE : 0.6861 (-10.31%)
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE)...

APRE : 0.6861 (-10.31%)
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor ...

APRE : 0.6861 (-10.31%)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team...

APRE : 0.6861 (-10.31%)
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Patient experienced only Grade 1 adverse events  Represents second patient with PR to harbor PPP2R1A...

APRE : 0.6861 (-10.31%)

Business Summary

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development...

See More

Key Turning Points

3rd Resistance Point 0.8657
2nd Resistance Point 0.8154
1st Resistance Point 0.7507
Last Price 0.6861
1st Support Level 0.6357
2nd Support Level 0.5854
3rd Support Level 0.5207

See More

52-Week High 2.2200
Fibonacci 61.8% 1.5813
Fibonacci 50% 1.3840
Fibonacci 38.2% 1.1867
Last Price 0.6861
52-Week Low 0.5480

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.